Effect of multiparametric MRI and ultrasound-guided biopsy for early prostate cancer detection: A prospective cohort study.

It is essential to detect clinically significant prostate cancer (csPCa) in an early and precise manner. However, there are challenges given that the usual TRUS-guided biopsy may leave tumors undiagnosed, or only detect indolent disease. In this prospective cohort study of 200 patients, we compared the diagnostic accuracy of multiparametric MRI (mpMRI) with TRUS-guided biopsy. The study found better sensitivity (91% vs 68%) and specificity (76% vs 60%) than TRUS biopsy, and identified 22% more clinically significant cancers than TRUS biopsies. In addition, mpMRI showed better positive predictive value and negative predictive value than TRUS-guided biopsy; this suggests general advantage in diagnostic accuracy and performance for mpMRI. Data shows, there is support for mpMRI having improved efficacy as a method of detecting clinically significant prostate cancer early compared to TRUS-guided biopsy.